← Back to all trials
Completed
NCT07279636
A Study to Evaluate Single Doses of Alpha-0261 in Healthy Adult Volunteers
Conditions: Healthy Volunteers
Sex: All
Ages: 18 Years – 55 Years
Healthy volunteers: Yes
Phase: PHASE1
Enrollment: 55
Sponsor: AlphaMol Science Ltd. (Shanghai)
Location: Bishan Hospital of Chongqing Chongqing
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Alpha-0261 tablets after single oral administration in healthy adult volunteers.
Eligibility Criteria
Inclusion Criteria:
* Aged ≥ 18 and ≤ 55, male or female
* Weight: ≥ 50 kg for males, ≥ 45 kg for females; 19 kg/m2 ≤ body mass index (BMI) ≤ 28 kg/m2
* In general good health
Exclusion Criteria:
* Have a history of any severe allergic reaction or anaphylaxis
* Any condition, which in the investigator's opinion might jeopardize participant's safety or compliance with the protocol
* Have clinically significant abnormalities on clinical laboratory results
Source: ClinicalTrials.gov (NCT07279636). StuddyBuddy aggregates publicly available trial information.
